Thursday, February 28, 2013 10:37:05 AM
I won't rehash Otrexup for RA, but I show that contributing about $12 in share price ($200M sales, .67 EPS contribution, P/E 20).
With respect to Otrexup for psoriasis, below is my model.
No. of ppl w/ psoriasis - 7.5M
% taking MTX - 13%
% to use Otrexup for psoriasis - 15% mkt share capture
Annual patient cost - $1200
Gross revs @ peak - $175M (7.5M x .13 x .15 x 1200)
Profit margin - 55%, Tax - 25%
Net profit 72M, or .52c EPS contribution
Multiplied by P/E of 20 is $10.3 contribution to share price.
In summary - Otrexup, granted it has good market penetration for multiple indications, should be worth $20 towards ATRS's share price.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM